- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05910996
Prediction of Conversion From Vv-ECMO to Va-ECMO in COVID-19 Patients (ECMOPred-vvva)
In December 2019, cases of a novel lung disease, later referred to as COVID-19, were first reported in China. The virus SARS-CoV-2 was identified as the causative agent. Due to the sharp increase in the number of cases worldwide, a pandemic outbreak was declared by WHO in March 2020.
The infection presents with a broad clinical spectrum. Frequently, there is respiratory infection with fever (80%), dry cough (56%), fatigue (22%), and muscle pain (7%), but completely asymptomatic infection is also possible. Severe courses may be associated with pneumonia resulting in acute respiratory distress syndrome (ARDS) requiring intensive care.
In the context of intensive care therapy, it is sometimes necessary to use extracorporeal organ replacement procedures due to increasing lung failure. In this context, extracorporeal membrane oxygenation (ECMO) was used during the pandemic. With this procedure it is possible to replace on the one hand the oxygenation and ventilation function of the lung and on the other hand additionally the pumping function of the heart, if configured appropriately. The switch from venovenous (vv) configuration, with which only lung function is replaced, to venoarterial (va) configuration (lung function and heart function are replaced) is made in cases of intensive care necessity, e.g., increasing decompensation of heart failure.
Heart failure manifests itself, among other things, through insufficient pumping function of the heart muscle. This results in an undersupply of peripheral tissues with arterial blood, leading to increased anaerobic glycolysis. Lactate and B-type natriuretic peptide (BNP) are used as surrogate parameters of this undersupply. Increased oxygen depletion from oxygen available in arterial blood is detected by the surrogate parameter central venous oxygen saturation (ScvO2).
In addition to ECMO, drug interventions are also used to improve cardiorespiratory performance at various doses. As described by Suwalski et al, there may be a relationship between this drug therapy and conversion from vv to va ECMO.
Currently, few studies exist on conversion from vv-ECMO to va-ECMO. In this regard, Suwalski et al. describe a population that experienced any ECMO therapy for a maximum period of 16.5 ± 10.0 days, with the group with conversion receiving 17.8 ± 10.5 days of therapy and the group without conversion receiving 16.4 ± 9.4 days. The need for conversion to va-ECMO requires additional expertise that is not readily available despite acute intensive care transport readiness. It is likely that by predicting the need for conversion, early logistical planning for transfer to an appropriate center with experience and equipment can occur, or if transfer is not necessary, staffing and equipment preparation can occur earlier and more safely. As described by Falk et al, planned and prepared conversion can also be expected to have an impact on patient* survival.
The aim of this retrospective, exploratory data analysis is to predict conversion before placement of vv-ECMO within 30 days from ICU care from vv-ECMO to va-ECMO in COVID-19 patients.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Upper Austria
-
Linz, Upper Austria, Austria, 4020
- Kepler University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- COVID-19 positive patients aged 18 years or older that were treated in intensive care at the study center between 2019-12-01 and 2023-04-15.
Exclusion Criteria:
- Patients in which ECMO therapy was started outside of the study center.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Conversion from vv-ECMO to va-ECMO Positive
|
Conversion from vv-ECMO to va-ECMO
|
Conversion from vv-ECMO to va-ECMO Negative
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Confusion Matrix
Time Frame: 2019-12-01 to 2023-07-01
|
Confusion Matrix for Classification of Conversion from vv-ECMO to va-ECMO
|
2019-12-01 to 2023-07-01
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: 2019-12-01 to 2023-07-01
|
7, 14, and 30 Day-In Hospital Mortality
|
2019-12-01 to 2023-07-01
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- ECMOPred-vvva
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ARDS Due to Disease Caused by SARS Co-V-2
-
Central Hospital, Nancy, FranceRecruitingRespiratory Compliance | ARDS Due to Disease Caused by SARS Co-V-2 | Sequels of COVIDFrance
-
The First Hospital of Jilin UniversityCompletedARDS Due to Disease Caused by SARS Co-V-2China
-
Pomeranian Medical University SzczecinNot yet recruitingOxygen Deficiency | Corona Virus Infection | ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2Poland
-
Hopital of MelunCompletedCOVID-19 Pneumonia | ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2France
-
AstraZenecaTerminatedPrevention of Infectious Disease Caused by SARS-CoV-2Japan
-
AstraZenecaCompletedPrevention of Infectious Disease Caused by SARS-CoV-2Japan
-
TakedaCompletedPrevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Japan
-
A.O. Ospedale Papa Giovanni XXIIICompletedSevere Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 InfectionItaly
-
Hospital Universitario Ramon y CajalRecruitingCOVID-19 Acute Respiratory Distress Syndrome | ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2Spain
-
Jeffrey BluestoneNational Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance...TerminatedAcute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoVUnited States
Clinical Trials on Conversion from vv-ECMO to va-ECMO
-
Meir Medical CenterNot yet recruitingNeurocognitive DysfunctionIsrael
-
University Hospital, GhentCompletedQuality of Life | Death | Extracorporeal Membrane Oxygenation Complication | COVID-19 Acute Respiratory Distress SyndromeBelgium
-
Australian and New Zealand Intensive Care Research...The AlfredCompletedCovid19 | Mechanical Ventilation Complication | Severe Acute Respiratory InfectionAustralia, Germany
-
Dr. Alexander SupadyCompletedCOVID-19 | Respiratory Failure | SARS-CoV Infection | Coronavirus | Cytokine StormGermany
-
Dr. Alexander SupadyCompletedCOVID-19 | SARS-CoV 2 | Extracorporeal Membrane Oxygenation | ARDSGermany
-
Dr. Alexander SupadyLudwig-Maximilians - University of Munich; University of Ulm; Klinikum Ibbenbüren and other collaboratorsSuspendedCoronavirus Infection | SARS-CoV 2 | Respiratory Failure | Extracorporeal Membrane Oxygenation | COVID | Cytokine StormGermany
-
Christian SchulzeRecruiting
-
Medical University of ViennaRecruitingCarbon DioxideAustria
-
Assistance Publique - Hôpitaux de ParisSuspendedAcute Myocardial Infarction | Cardiogenic ShockFrance
-
Xijing HospitalRecruitingHigh-Risk Percutaneous Coronary Intervention (High-risk PCI) | Left Ventricular Assist DevicesChina